What is Zacks Research’s Forecast for Humana Q1 Earnings?

Humana Inc. (NYSE:HUM) – Analysts at Zacks Research lowered their Q1 2026 earnings estimates for Humana in a note issued to investors on Wednesday, April 15th. Zacks Research analyst Team now forecasts that the insurance provider will earn $9.03 per share for the quarter, down from their prior forecast of $9.05. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s FY2026 earnings at $9.90 EPS, FY2027 earnings at $14.16 EPS and FY2028 earnings at $18.34 EPS.

Several other analysts have also commented on the stock. Oppenheimer set a $250.00 price target on shares of Humana in a research report on Thursday, February 12th. Wells Fargo & Company increased their price target on shares of Humana from $206.00 to $227.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 7th. Robert W. Baird decreased their price target on shares of Humana from $264.00 to $205.00 and set a “neutral” rating for the company in a research report on Wednesday. Deutsche Bank Aktiengesellschaft set a $180.00 price target on shares of Humana and gave the company a “hold” rating in a research report on Friday, February 13th. Finally, Evercore increased their price target on shares of Humana from $180.00 to $195.00 in a research report on Wednesday, April 8th. Seven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $222.09.

Humana Stock Performance

HUM stock opened at $205.09 on Friday. The firm has a market cap of $24.62 billion, a price-to-earnings ratio of 20.89, a PEG ratio of 2.15 and a beta of 0.44. The firm has a 50-day simple moving average of $181.32 and a two-hundred day simple moving average of $230.97. Humana has a one year low of $163.11 and a one year high of $315.35. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS.

Hedge Funds Weigh In On Humana

Several hedge funds have recently modified their holdings of HUM. Capital International Investors increased its holdings in shares of Humana by 113.9% during the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after acquiring an additional 3,097,571 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Humana by 273.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,488,261 shares of the insurance provider’s stock valued at $907,541,000 after acquiring an additional 2,553,509 shares in the last quarter. Norges Bank acquired a new position in shares of Humana during the fourth quarter valued at about $456,632,000. Wellington Management Group LLP increased its holdings in shares of Humana by 4,481.7% during the fourth quarter. Wellington Management Group LLP now owns 1,196,502 shares of the insurance provider’s stock valued at $306,460,000 after acquiring an additional 1,170,387 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Humana by 914.5% during the fourth quarter. Franklin Resources Inc. now owns 1,255,665 shares of the insurance provider’s stock valued at $321,613,000 after acquiring an additional 1,131,893 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Activity

In related news, insider Sanjay K. Shetty acquired 810 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were purchased at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the acquisition, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. The trade was a 7.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by company insiders.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.7%. Humana’s dividend payout ratio is 36.05%.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana secured a $30 million settlement from Lupin’s U.S. unit over an antitrust claim, a cash recovery that removes litigation uncertainty and modestly improves near-term cash/earnings visibility. Article Title
• Positive Sentiment: Humana announced a quarterly dividend of $0.885 per share (record June 26, paid July 31), which supports yield-focused investors and signals board confidence in cash generation. Dividend Announcement
• Neutral Sentiment: Jim Cramer discussed Humana’s business on CNBC/linked coverage, increasing retail investor attention — media mentions can boost trading volume and momentum but don’t change fundamentals by themselves. Article Title
• Negative Sentiment: Zacks Research sharply downgraded Humana from “Hold” to “Strong Sell” and trimmed multiple near- and multi‑year EPS estimates (Q1 2026, FY2026–FY2028 and several 2027 quarters). The downgrade and the handful of small estimate cuts increase selling pressure and signal analyst concerns about near-term profitability. Zacks Research
• Negative Sentiment: Humana disclosed a data breach affecting customers in Texas and five other states — this raises potential customer, regulatory and remediation costs and could create reputational headwinds. Data Breach Article

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.